Several preclinical studies have shown that PET imaging, for example with tracers targeting TSPO or CXCR4, can quantify changes in myocardial inflammation after treatment with conventional heart failure therapies, such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers [38•, 40, 65, 66]. The gene discussed is CXCR4; the disease is heart failure.